Abstract

Following the survival benefit demonstrated in the OlympiA trial, one year of adjuvant olaparib is now recommended for all patients with germline BRCA1/2 pathogenic/likely pathogenic variants (PV) and high-risk, HER2-negative early breast cancer after chemotherapy. However, optimal identification of high-risk patients who may derive benefit from this genomically-directed therapy is debated. In this study, we sought to characterize the real-world proportion of gBRCA1/2 PV carriers eligible for adjuvant olaparib according to the OlympiA criteria, and to compare clinicopathologic characteristics and outcomes between eligible and ineligible patients.

Details

Title
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer
Author
Morganti, Stefania 1 ; Jin, Qingchun 2   VIAFID ORCID Logo  ; Vincuilla, Julie 3 ; Buehler, Ryan 4 ; Ryan, Sean 5 ; Stokes, Samantha 6 ; Parker, Tonia 5 ; Mittendorf, Elizabeth A. 7 ; King, Tari A. 7 ; Weiss, Anna 8 ; Partridge, Ann H. 9   VIAFID ORCID Logo  ; Bychkovsky, Brittany L. 10   VIAFID ORCID Logo  ; Curigliano, Giuseppe 11   VIAFID ORCID Logo  ; Tayob, Nabihah 12   VIAFID ORCID Logo  ; Lin, Nancy U. 9 ; Garber, Judy E. 10 ; Tolaney, Sara M. 9   VIAFID ORCID Logo  ; Lynce, Filipa 9   VIAFID ORCID Logo 

1  Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Broad Institute of MIT and Harvard, Boston, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623) 
2  Dana-Farber Cancer Institute, Department of Data Science, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
3  Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896) 
4  Dana-Farber Cancer Institute, Division of Cancer Genetics and Prevention, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
5  Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896) 
6  Broad Institute of MIT and Harvard, Boston, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623) 
7  Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Brigham and Women’s Hospital, Division of Breast Surgery, Department of Surgery, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294) 
8  Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Brigham and Women’s Hospital, Division of Breast Surgery, Department of Surgery, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294); University of Rochester Medical Center, Division of Surgical Oncology, Rochester, USA (GRID:grid.412750.5) (ISNI:0000 0004 1936 9166) 
9  Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
10  Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Dana-Farber Cancer Institute, Division of Cancer Genetics and Prevention, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
11  University of Milan, Department of Oncology and Hemato-Oncology, Milan, Italy (GRID:grid.4708.b) (ISNI:0000 0004 1757 2822); European Institute of Oncology IRCCS, Milan, Italy (GRID:grid.15667.33) (ISNI:0000 0004 1757 0843) 
12  Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Dana-Farber Cancer Institute, Department of Data Science, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
Pages
28
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
23744677
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1038/s41523-024-00632-8
ProQuest document ID
3039629899
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.